Navigation Links
ZFP in Medical News

Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009

Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of as y...

Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference

...ill provide an update on the progress of Sangamo's zfp Therapeutic(TM) development programs and an overvi...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...

Sangamo BioSciences Reports First Quarter 2009 Financial Results

...n in Nature of the successful application of zfp technology for the efficient generation of maize p...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...

Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives

...ve had together to confirm our conviction that the zfp platform has the ability to truly transform the fi... Mr. Peribere. "We have established that Sangamo's zfp technology can be used to regulate and modify gene... clinical data from our Phase 1b trial of our lead zfp Therapeutic(TM), SB-509, an activator of vascular ...

Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference

...ill provide an update on the progress of Sangamo's zfp Therapeutic development programs and an overview o...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... Phase 1 clinical trials are ongoing to evaluate a zfp Therapeutic for peripheral artery disease. Other t...

New Gene Therapy Treats Diabetic Neuropathy

...Faculty of Life Sciences. ‘Our approach to gene therapy is quite different to previous attempts at treatment: we use a DNA-binding protein called zfp TFTM to poke life into the patient's own genes and produce a growth factor that has a role in nerve protection and regeneration. ‘As the data in ...
ZFP in Medical Technology

Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting

Presentation Details Statistically Significant and Clinically Relevant Results for SB-509 in Development for Treatment of Diabetic Neuropathy SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of encouraging Phase 1b ...

Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

ZFN Modified Cells Show Glioblastoma Killing in the Presence of Dexamethasone in Mouse Tumor Model SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced the presentation of positive data in a mouse tumor model from its ZF...

Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy

Milestone Triggers Payment to Sangamo from JDRF RICHMOND, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that the company has completed enrollment of its randomized, double-blind, repeat-dosing, placebo-controlled, multi-center P...

Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting

Statistically Significant Improvements in Function in Spinal Cord Injury Model With ZFP TF Treatment RICHMOND, Calif., May 03, 2007 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the presentation of preclinical data from its ZFP Therapeutic(TM) program in nerve regeneration at...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...ne regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. The most advanced zfp Therapeutic(TM) development program is currently i...

Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences

...ill provide an update on the progress of Sangamo's zfp Therapeutic(TM) development programs and an overvi...ne regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

... in laboratories worldwide and we expect Sangamo's zfp technology to be nothing short of revolutionary fo...past year has been a year of real progress for our zfp technology platform," said Edward Lanphier, presid...us to make significant progress in moving our lead zfp Therapeutic into multiple Phase 2 clinical trials ...

Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)

...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. Sangamo...

Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells

...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... Phase 1 clinical trials are ongoing to evaluate a zfp Therapeutic for peripheral artery disease. Other t...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. Sangamo...
ZFP in Biological News

Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection

Sangamo BioSciences, Inc. today announced that data from its program to develop a ZFP Therapeutic for HIV/AIDS were presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. The study represents the first demonstration that cells can b...

Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference

...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... Phase 1 clinical trials are ongoing to evaluate a zfp Therapeutic for peripheral artery disease. Other t...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TFTM) that can control ...

Trial success for diabetic nerve therapy

...s Faculty of Life Sciences. "Our approach to gene therapy is quite different to previous attempts at treatment: we use a DNA-binding protein called zfp TFTM to poke life into the patient's own genes and produce a growth factor that has a role in nerve protection and regeneration. "As the data in th...
ZFP in Biological Technology

Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting

Progenitor Cell Mobilization Observed in Subjects with Critical Limb Ischemia Treated with ZFP Therapeutic MIAMI, May 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of data from a Phase 1 clinical trial of a zinc finge...

Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals

RICHMOND, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that it had entered into a License Agreement with Open Monoclonal Technologies (OMT), a private company based in Palo Alto, California. Under this agreement, Sangamo will provid...

Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production

Companies Agree to Expanded Access to ZFN Technology To Potentially Improve Protein Production RICHMOND, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that it has entered into a second Research and License Agreement...

Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting

Statistically Significant Improvements in Function and Tissue Preservation with ZFP TF Treatment in Spinal Cord Injury Model SAN DIEGO, Nov. 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of preclinical data from its ZFP Therape...

Sangamo BioSciences Reports Second Quarter 2009 Financial Results

...hlights Presentation of positive Phase 2 zfp Therapeutic data at ADA 2009. Sangamo announced t...unreleased positive Phase 2 clinical data from its zfp Therapeutic(TM) program to develop SB-509 as a tre...angamo demonstrating the successful application of zfp technology for the efficient generation of maize p...

Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast

...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...tion. Sangamo is also developing sequence-specific zfp Nucleases (ZFN(TM)) for gene modification. The most advanced zfp Therapeutic(TM) development program is currently i...

Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference

...ill provide an update on the progress of Sangamo's zfp Therapeutic(TM) development programs and an overvi...ene regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...

Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research

...valuate the safety and tolerability of SB-728-T, a zfp Therapeutic based on Sangamo's CCR5-disrupting ZFN...our efforts to develop the next generation of this zfp Therapeutic, an in-vivo formulation for direct i...ne regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i...

Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species

...Sangamo demonstrated the successful application of zfp technology for the efficient generation of maize p... , scientists at Dow AgroSciences and Sangamo used zfp Nucleases (ZFNs(TM)) to introduce a herbicide tole...ul demonstration of the broad applicability of our zfp technology platform," stated Philip Gregory, D. Ph...

Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast

...ne regulation and modification. The most advanced zfp Therapeutic(TM) development program is currently i... trial to evaluate safety and clinical effect of a zfp Therapeutic for the treatment of HIV/AIDS. Other t...ognize a specific DNA sequence Sangamo has created zfp transcription factors (ZFP TF(TM)) that can contro...
Other Tags
(Date:4/23/2014)... proliferation of endogenous neural precursor cells cannot alone ... From the perspective of neural plasticity, Dr. Yun ... China observed the effects of functional electrical stimulation ... expression of basic fibroblast growth factor and epidermal ... infarct side. The researchers found that functional electrical ...
(Date:4/22/2014)... the New Jersey Institute of Technology (NJIT) today ... the launch of the New Jersey Innovation Institute ... model for business innovation through the leveraging of ... U.S. Senator Cory Booker, Panasonic Corp. of North ... Lieutenant Governor Kim Guadagno, New Jersey Secretary of ...
(Date:4/22/2014)... primary care for low-income patients may ease the ... while improving patient health, researchers have concluded. , ... clinics that avoid costs associated with insurance administration ... admission rates and emergency room visits, according to ... , The researchers estimated that the major ...
(Date:4/22/2014)... risk of pregnancy among women using a newer method ... 10 times greater over a 10-year period than using ... researchers at Yale University and UC Davis has found. ... Contraception , the study found the higher risk ... the brand name Essure. , "This study provides ...
(Date:4/22/2014)... Johns Hopkins scientists have found a way to block ... development of atherosclerosis, the main cause of heart attacks ... humans. The condition develops when fat builds inside blood ... hardened, greatly reducing their ability to feed oxygen-rich blood ... a series of experiments, described April 7 in the ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
(Date:4/23/2014)... ripping open a dinner roll, a fuel cell catalyst ... hydrogen molecule. Now researchers have captured a view of ... its hydrogen feast. The view confirms previous hypotheses and ... better for alternative energy uses. , This study is ... hydrogen halves end up in the structure of a ...
(Date:4/23/2014)... of a unique rhythmic sound, recorded for decades in ... Antarctic minke whale ( Balaenoptera bonaerensis ). First described ... thought it sounded like a duck, the bio-duck sound ... Ocean, but its source has remained a mystery, until ... researchers deployed acoustic tags on two Antarctic minke whales ...
(Date:4/23/2014)... Buenos Aires yesterday, Argentina joins the European Molecular ... The move strengthens the ties between the European ... Argentinian scientists access to EMBL,s world-class facilities and ... since its inception, fostering excellent life science research ... core of EMBL,s mission," says EMBL Director General ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
Other Contents